Who Prioritizes Innovation? R&D Spending Compared for Dr. Reddy's Laboratories Limited and Viking Therapeutics, Inc.

Comparing R&D priorities in pharmaceuticals: Dr. Reddy's vs. Viking Therapeutics

__timestampDr. Reddy's Laboratories LimitedViking Therapeutics, Inc.
Wednesday, January 1, 20141240200000022223073
Thursday, January 1, 2015174490000006966842
Friday, January 1, 2016178340000009000499
Sunday, January 1, 20171955100000013741186
Monday, January 1, 20181826500000019040000
Tuesday, January 1, 20191560700000023559000
Wednesday, January 1, 20201541000000031931000
Friday, January 1, 20211654100000044981000
Saturday, January 1, 20221748200000054234000
Sunday, January 1, 20231938100000063806000
Monday, January 1, 202422873000000
Loading chart...

Unleashing insights

Innovation in Pharmaceuticals: A Comparative Analysis

In the ever-evolving pharmaceutical industry, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Dr. Reddy's Laboratories Limited and Viking Therapeutics, Inc. offer a fascinating contrast in their R&D investments over the past decade. From 2014 to 2023, Dr. Reddy's consistently allocated a significant portion of its resources to R&D, with expenditures growing by approximately 85% over this period. In contrast, Viking Therapeutics, a smaller player, has shown a remarkable increase in its R&D spending, rising nearly 187% from 2014 to 2023, albeit from a much smaller base. This disparity highlights the different scales and strategies of these companies. While Dr. Reddy's focuses on maintaining its competitive edge, Viking Therapeutics is aggressively investing in innovation to carve out its niche in the market. The data for 2024 is incomplete, indicating ongoing developments in this dynamic field.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025